Larvol Delta - AltruBio-Announces-Completion-of-Enrollment-in-Phase-1-Clinical-Study-of-Neihulizumab-ALTB168-in-Patients-with-SteroidRefractory-Acute-GraftVersusHost-Disease-SRaGVHD

neihulizumab (ALTB-168) - AltruBio

https://www.globenewswire.com/news-release/2022/05/12/2442346/0/en/AltruBio-Announces-Completion-of-Enrollment-in-Phase-1-Clinical-Study-of-Neihulizumab-ALTB-168-in-Patients-with-Steroid-Refractory-Acute-Graft-Versus-Host-Disease-SR-aGVHD.html

May 12, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next